Edition:
United States

Cerulean Pharma Inc (CERU.OQ)

CERU.OQ on NASDAQ Stock Exchange Global Market

0.91USD
29 Mar 2017
Change (% chg)

-- (--)
Prev Close
$0.91
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
378,947
52-wk High
$4.33
52-wk Low
$0.64

Latest Key Developments (Source: Significant Developments)

Cerulean Pharma and Daré Bioscience enter into stock purchase agreement
Monday, 20 Mar 2017 08:00am EDT 

Cerulean Pharma Inc : Cerulean pharma and daré bioscience enter into stock purchase agreement . Cerulean pharma inc - cerulean enters into two agreements to sell assets . Cerulean pharma inc- cerulean pays off debt facility and announces reduction in force . Cerulean pharma inc - stockholders of daré bioscience will receive shares of newly issued cerulean common stock . Cerulean pharma inc - outstanding daré bioscience options and convertible securities will be assumed by cerulean . Cerulean pharma inc - sabrina martucci johnson to be named ceo of combined company . Cerulean pharma inc - transaction has been unanimously approved by boards of directors of both companies . Cerulean pharma inc - cerulean sold its clinical product candidates, crlx101 and crlx301, for $1.5 million to bluelink pharmaceuticals . Cerulean pharma inc - cerulean also entered into an agreement with novartis . Cerulean pharma inc-in connection with the transactions, it is paying off its debt facility with hercules capital, inc. . Cerulean pharma inc - novartis will acquire all rights to cerulean's dynamic tumor targeting(tm) platform for $6 million . Cerulean pharma-board of combined company will consist of five members, three to be designated by daré and two to be designated by cerulean . Cerulean pharma inc- upon close of proposed transaction, board of directors of combined company will consist of five members.  Full Article

Cerulean Pharma reports Q3 2016 financial results
Thursday, 3 Nov 2016 04:11pm EDT 

Cerulean Pharma Inc - : Announced reduction in force of approximately 48% percent, which company expects to be substantially completed by end of 2016 . Announced reduction in force of approximately 48% percent, which company expects to be substantially completed by end of 2016 . In quarter, announced 5-target collaboration with novartis to combine Co's proprietary NDC technology with Novartis-selected compounds .Cerulean reports third quarter 2016 financial results and provides corporate update.  Full Article

Cerulean Pharma says reducing workforce by about 48 pct
Thursday, 18 Aug 2016 04:01pm EDT 

Cerulean Pharma Inc : Cerulean announces reduction in force . Says reducing its workforce by about 48 pct, to a total of 23 full-time equivalent employees . Says expects reduction plan to be substantially completed by end of 2016 . Says workforce reduction is designed to reduce operating expenses while co refocuses its clinical strategy for CRLX101 .Expects reduction in force to result in about $5 million in reduced annualized operating expenses.  Full Article

Cerulean says has enough cash to fund planned ops into Q2 2017
Thursday, 4 Aug 2016 04:05pm EDT 

Cerulean Pharma Inc : Cerulean reports second quarter 2016 corporate highlights and financial results . Believes its cash and cash equivalents are sufficient to fund its planned operations into q2 of 2017 .Qtrly net loss attributable to stockholders for q2 was $10.9 million, compared to net loss attributable to common stockholders of $9.9 million.  Full Article

Cerulean Pharma receives FDA fast track designation for ovarian cancer treatment
Tuesday, 19 Jul 2016 07:30am EDT 

Cerulean Pharma Inc : Receives FDA fast track designation for CRLX101 for the treatment of platinum-resistant ovarian cancer .Expects to provide an update on CRX101 at European Society For Medical Oncology 2016 Congress.  Full Article

Cerulean Pharma Inc announces clinical collaboration with AstraZeneca and the National Cancer Institute
Tuesday, 17 Nov 2015 07:00am EST 

Cerulean Pharma Inc:Announces clinical collaboration with AstraZeneca and the National Cancer Institute to evaluate the combination of LYNPARZA and CRLX101.Says collaboration to explore synergistic effects of Astrazeneca's LYNPARZA, and CRLX101, Cerulean's inhibitor of Topoisomerase 1.Under this collaboration, AstraZeneca will supply LYNPARZA, Cerulean will supply CRLX101, and the NCI will fund and conduct the clinical trial under Cooperative Research and Development Agreements with the companies.  Full Article

Cerulean Pharma Inc announces crlx101 advances to second stage of phase 2 clinical trial
Wednesday, 30 Sep 2015 07:00am EDT 

Cerulean Pharma Inc:Announces crlx101 advances to second stage of phase 2 clinical trial of crlx101 in combination with avastin in relapsed ovarian cancer.To date, 8 of 15 patients have achieved at least six months of progression free survival, with three patients still ongoing.  Full Article

Cerulean Pharma appoints Interim Chief Financial Officer
Wednesday, 27 May 2015 08:00am EDT 

Cerulean Pharma Inc:Appoints Gregg Beloff, J.D., M.B.A., as Interim Chief Financial Officer.  Full Article

Cerulean Pharma Inc's CRLX101 Receives Orphan Drug Designation from the FDA for the Treatment of Ovarian Cancer
Tuesday, 26 May 2015 06:45am EDT 

Cerulean Pharma Inc:Says U.S. Food and Drug Administration, or FDA, has granted orphan drug designation to CRLX101 for the treatment of ovarian cancer.Says Phase 2 trial of CRLX101 plus Avastin(reg) is enrolling patients, and a Phase 1b trial of CRLX101 plus weekly paclitaxel in collaboration with the GOG Foundation is expected to start enrolling patients in the 2(nd)quarter of 2015.  Full Article

Cerulean Pharma Inc closes public offering of common stock
Friday, 10 Apr 2015 09:31am EDT 

Cerulean Pharma Inc:Announced the closing of its underwritten public offering of 6,716,000 shares of common stock, including 876,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $6.00 per share.Gross proceeds to Cerulean from this offering were about $40.3 mln, before deducting underwriting discounts and commissions and offering expenses payable by Cerulean.Leerink Partners LLC and Barclays Capital Inc. acted as joint book-running managers for the offering.Canaccord Genuity Inc., JMP Securities LLC and Wedbush PacGrow acted as co-managers for the offering.  Full Article

More From Around the Web